Celldex Therapeutics Inc (NASDAQ:CLDX) traded at $27.60 at close of the session on current trade day and made an upward move of 3.84% on its previous day’s price.
Looking at the stock we see that its previous close was $26.58 and the beta (5Y monthly) reads 1.594 with the day’s price range being $26.54 – $28.88. In terms of its 52-week price range, CLDX has a high of $53.18 and a low of $22.93. The company’s stock has gained about 5.91% over that past 30 days.
Celldex Therapeutics Inc has a market cap of $1.83 billion and is expected to release its quarterly earnings report in February.
On the other hand, looking at the outlook for the CLDX stock, short term indicators assign the stock an average of 50% Sell, while medium term indicators assign it an average of 50% Sell.
Based on estimates by 4 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 1 have rated the Celldex Therapeutics Inc (CLDX) stock as a Hold, while 3 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.
Looking further, we note the current price level is 6.67% off its SMA20 and 5.44% from its 50-day simple moving average. The RSI (14) is pointing at 59.36 while the volatility over the past week is 5.50% and jumps to 5.08% over the past one month. The beta value is 1.61, while the average true range (ATR) is currently pointing at 1.33. The average price target for the stock over the next 12 months is $62, with the estimates having a low of $44 and a high of $80. These price ends are -59.42% and -189.86% off the current price level respectively, although investors could be excited at the prospect of a -124.64% if the CLDX share price touches on the median price of $62.
Coming back to Celldex Therapeutics Inc (NASDAQ:CLDX), we note that the average 3-month trading volume was 985.26K, while that of the preceding 10-day period stands at 0.97 million. Current shares outstanding are 66.34 million.
The insiders hold 2.48% of the company’s shares while institutions hold 107.05%. The data shows that short shares as of 2024-12-13, stood at 7.31 million at a short ratio of 7.07. This represents a 1274.00 short interest in shares outstanding on 2024-12-13. Shares short fall in December from the previous month at 7.83 million. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock 9.22% up in year-to-date price movement.
